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Abstract
Pericardial effusion represents a common postoperative complication in cardiac surgery. Nonetheless, it can be
resistant to conventional therapy leading to prolonged in-hospital stay and worsening of clinical conditions.
Recent literature shows that colchicine therapy should be useful in the treatment of recurrent post surgical
pericardial effusion.
Hereby we report the case of a patient with postsurgical recurrent effusion treated with colchicine, and a review of
literature concerning the use of this old drug.
Text
Pericardial effusion represents a common postoperative
complication in cardiac surgery. Sometimes it can be
resistant to conventional therapy leading to prolonged
in-hospital stay and worsening of clinical condition.
In the last twenty years colchicine was reported to be
clinical effective although most of Authors have pub-
lished their experience based upon incomplete and
sometimes anedoctical experience. Starting from a case
of patients successfully treated with this drug we present
a review concerning the more recent and statistically
based studies about the treatment with this old but
actually drug.
Case Report
A 47-year-old male underwent elective coronary artery
bypass grafting. The postoperative intensive care unit
stay was uneventful, the postoperative echocardiogram
did not showed abnormalities and the patient was dis-
charged on 100 mg cardioaspirin once daily. Five days
after the discharge, the patient developed ongoing dys-
pnea and was referred to our department. The echocar-
diogram demonstrated a large amount of pericardial
effusion. Subxiphoid pericardiotomy was performed.
The analysis of pericardial fluid excluded the
hemorrhagic etiology. Cytology and histology was nega-
tive. The drainage catheter was left in place tree days
until absence of pericardial effusion was detected by
echocardiographyc control.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and
corticosteroids were initiated. After two weeks the echo-
cardiographic control revealed a new onset pericardial
effusion that was again treated surgically.
Considering the failure of the conventional therapy,
the patient was treated with 2 mg/die colchicine for 1
month followed by 1 mg/die for a further 6 months,
without recurrence of the effusion after follow-up of 6
months. No side-effects were observed.
Discussion
Postpericardiotomy syndrome (PPS) is a frequent com-
plication of cardiac operations affecting from 20 to 40%
of patients appearing within 6 months of the initial
operation with a median of 4 weeks after heart surgery
[1-5]. The PPS is acutely provoked by a greater antiheart
antibody response (antisarcolemmal and antifibrillary)
and appear to be variants of a common immunopathic
process [1-5].
Clinically is characterized by fever, eosinophilia,a n d
pleuritis. Additional findings include malaise, splinter
hemorrhages, leukocytosis, and an increased erythrocyte
sedimentation rate. Some patients have mild normocytic
anemia. Liver function test results are normal and chest * Correspondence: luca.dainese@ccfm.it
Dpt of Cardiovascular Surgery, University of Milan, Centro Cardiologico
Monzino IRCCS, Via Parea 4, 20138 Milan, Italy
Dainese et al. Journal of Cardiothoracic Surgery 2011, 6:96
http://www.cardiothoracicsurgery.org/content/6/1/96
© 2011 Dainese et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.radiography typically shows a characteristic bilateral
pleural effusion.
Standard pericardial effusion treatment usually con-
sists of administration of aspirin or nonsteroidal anti-
inflammatory drugs (NSAIDs) to decrease the fever
and the chest pain. Although most patients respond to
nonsteroidal anti-inflammatory drugs or corticosteroids
[4-8] the failure of this treatment is possible leading to
complications including cardiac tamponade, constric-
tive pericarditis, and occlusion of the coronary artery
bypass graft. In the last few years, colchicine has
appeared as an useful medical treatment for recurrent
pericardial effusion. Although the mechanism is not
fully understood [6-8] this drug seems to be safe and
effective.
Nowadays there is not uniformity on the dosage, the
duration of the therapy after the release of symptoms,
expecially after surgical procedure (Table 1).
Colchicine is a tricyclic alkaloid, and its pain-relieving
and anti-inflammatory effects were linked to its ability
to bind with tubulin inhibiting neutrophil motility and
activity, leading to a net anti-inflammatory effect. The
main anti-inflammatory mechanism of colchicine is via
inhibition of granulocyte migration into the inflamed
area inhibiting mitosis and affecting cells with high
turnover (GI tract, marrow) [1-5]. Thus it inhibits var-
ious leukocyte functions and depresses the action of the
leukocytes and of the fibroblasts at the site of the
inflammation [1-5]. The most common side effects of
colchicine involve the stomach and bowel and are dose
related including nausea, vomiting, abdominal pain, and
diarrhea.
Only in the past five years some Authors [4,9-14] pub-
lished the first multicenter result of use of colchicine in
pericardiac effusion based upon not only anedoctal
experiences. Specifically postsurgical studies use are
laking.
As a matter of fact the use of colchicine for pericardial
effusion start in 1987 when three patients were treated
for recurrences of acute pericarditis in with colchicine
(1 mg/day) with no relapses during a follow up period
of 15-35 months [6]. Even if some Authors [10] recom-
mend the use of the drug at the first recurrence as
adjunct to conventional therapy, others propose to con-
sider the drug only after failure of conventional thera-
pies for the second or subsequent recurrence [4,12,13].
Adler and collegues [8] suggested that the dose of col-
chicine is 1 mg/d for at least 1 year, with a gradual
tapering off. The need for a loading dose of 2 to 3 mg/d
at the beginning of treatment is unclear. Guindo et al.
[11] observed that colchicine (1 mg/day) is effective in
relieving pain and preventing recurrent pericarditis
treating a few number of patient treated also with pre-
dnisone (10-60 mg/day).
On the contrary Millaire and colleagues [9] used col-
chicine in recurrent pericarditis in nineteen consecutive
patients with recurrent pericarditis (two episodes or
more). Colchicine was given at a loading dose of 3 mg
and a maintenance dose of 1 mg daily for 1-27 months
with benefit and resolution of pericarditis in 14 patients.
The authors concluded that colchicine offered a very
good benefit/risk ratio without the need to use corticos-
teroids treatment. Guindo et Al. [7] in its more exten-
sive experience (51 patients) treated with corticosteroids
and NSAIDs or pericardiocentesis conclude that recur-
rences were generally minor and controlled with restitu-
tion if the patient were treated with colchicine therapy
(loading dose 0.5-3 mg/day with maintenance dose 0.5-2
mg/day). This results are confirmed by the Colchicine
for Acute Pericarditis (COPE) Trial [11] concerning the
use of colchicine in different type of pericardic syn-
drome also post pericardiectomy. One hundred twenty
patients with a first episode of acute pericarditis (idio-
pathic, acute, postpericardiotomy syndrome and connec-
tive tissue disease) entered a randomized, open-label
trial comparing aspirin plus colchicine (1.0 to 2.0 mg for
the first day followed by 0.5 to 1.0 mg/d for 3 months)
with treatment with aspirin alone. Even if colchicine
reduced symptoms at 72 hours and recurrence at 18
months it was discontinued in 5 patients because of
diarrhea. No other adverse events were noted. None of
120 patients developed cardiac tamponade or progressed
to pericardial constriction.
In the 2004 guidelines of the European Society of Car-
diology [4] suggested colchicine as a possible therapeutic
choice in acute pericarditis or for the treatment and
prevention of recurrent pericarditis (RP) after failure of
conventional therapies. The dose recommanded for RP
i s2m g / d a yf o ro n eo rt w od a yf o l l o w e db y1m g / d a y .
The dose for initial attack or prevention of recurrences
is 0.5 mg bid. In PPS the colchicine is recommanded for
several weeks or months, even after disapparence of
effusion. Imazio and collegues [11,13,15] in several
papers specify that the dose for prevention of PPS is 1.0
to 2.0 mg for the first day followed by a maintenance
dose of 0.5 to 1.0 mg daily for 1 month for patients ≥
70 kg. A lower dose (initial dose: 1.0 mg and mainte-
nance dose 0.5 mg daily) is given to patients < 70 kg or
intolerant to the highest dose (initial dose 1.0 mg BID
and maintenance dose of 0.5 mg BID).
The same dose is given in the CORE study [10], but
the time of administration is 6 months. Sagrista et Al.
[12] recommended starting dose of 1 mg every 12 hours
(the dose may be reduced to 0.5 every 12 hours in
patient with digestive intolerance). The duration of
treatment with colchicine is 1 year (0.5 mg- 1 mg/day).
In 2007 Imazio et Al. [13] recommend dose is 2 mg/
day for one-two days, followed by a maintenance dose
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Autors Loading Dose Maintenance Journal and year NSAIDs or Corticosteroids
Horneffer PJ et al. 2 mg/day for 1 or 2 days 1 mg/day for several weeks or months J Thor Cardiov Surgery 1990
and ESC 2004
Imazio et al. 1 or 2 mg/day (0.5 or 1 mg/
day < 70 kg)
0.5 or 1.0 mg/day for 3 months Circulation 2005 Aspirin 800 mg every 6 or 8 hours for 7 or 10 days (tapering
for 3-4 weeks)
Spodick DH
(Permayner-Miranda)
0.6 mg twice daily 0.6 mg twice daily for 1 or 2 weeks and
tapering for 1 or 2 weeks
JAMA 2003 Ibuprofen 800 mg every 8 hours
Millaire A et al 3 mg/day 1 mg/day (1 to 27 months -mean 7.7) Eur Heart J 1994
Guindo J et al 1 mg/day 1 mg/day Circulation 1990 Prednisone 20-60 mg/day
Lange RA 0.6 mg twice daily 0.6 mg twice daily NEJM 2004 Aspirin 2-4 mg/daily or Indometacin 75-225 mg/daily or
Ibuprofene 1600-3200 mg/daily
Adler Y et al 1 mg/day 1 mg/day Am J Cardiol 1994
De la Serna R et al 1 mg/day 1 mg/day Lancet 1987
Adler Y et al. 1 mg/day (1 or 6
months)
Clin Cardiol 1998 Aspirin
Adler Y et al. 2-3 mg/day (unclear) 1 mg/day at least 1 year Circulation 1998 Ibuprofen
Imazio M et al.
CORE
1.0-2.0 mg/day 0.5-1.0 mg/day for 6 months Arch Intern Med 2005 Aspirin 800 mg every 6 or 8 hours for 7 or 10 days (tapering
for 3-4 weeks)
Maisch B et al. 2 mg/day 1 mg/day Eur Heart J 2004
Shabetai R 2 mg/day 1 mg/day
Soler-Soler J et al 2 mg/day 1 mg/day Heart 2004
Imazio M et al.
COPPS (Prevention
PPS)
1.0-2.0 mg/day first day (1
mg/d < 70 kg)
0.5-1.0 mg/day for 1 month (0.5 mg/d < 70
kg)
Int J Cardiology 2006
Little and Freeman 2 mg/day 1 mg/day for 3 months Circulation 2006 Aspirin 650-975 mg every 6-8 h for 4 weeks
Imazio et al. 1 mg/day 1 mg/day Eur Heart Journal 2003 Aspirin 600-800 mg every 6 or 8 hours for 7 or 10 days
(tapering for 2-3 weeks)
Sagristà-Sauleda et al 1-2 mg 0.5-1 mg/day for 1 year Rev Esp Cardiol 2005
Finkelstein et al.
(Prevention PPS)
1.5 mg every 8 h/day for 1 month Herz 2002
Imazio et al. 2 mg 1 mg/day for 6-12 months J Cardiov Medicine 2007
Artom et al. 1 mg 1 mg Eu Heart Journal 2005
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4of 1 mg/day (0.5 mg twice daily). At doses of 1-2 mg/
day, colchicine is well tolerated even when given con-
tinuously over decades. Even if Spodick et Al. [16]
advises the best therapy for the acute and also for recur-
rent pericarditis combined ibuprofen (800 mg every 8
hours) with colchicine (0.6 mg twice daily) for 7 to 14
days followed by tapering for another 1 or 2 weeks
Artom et al. [14] found that treatment with colchicine is
highly effective in preventing recurrent pericarditis,
while pretreatment with corticosteroids exacerbates and
extends the course of recurrent pericarditis. Comparing
two surgical group pretreated with colchicine (1.5 mg/
day for one month) and placebo Finkelstein Y et al. [17]
found significantly less occurrence of pericardial effusion
in first group (10% vs. 20%).
Considering the different experiences above men-
tioned we give to the patient a 2 mg/die dose of colchi-
cine for 1 month followed by 1 mg/die for a further 6
months without echocardiographyc signs of recurrent
pericardial effusion.
Recent literature shows that colchicine therapy should
be usefull in treatment of recurrent post surgical peri-
cardial effusion.
Neverthless post surgical large studies are necessary to
state definitely the use of colchicine therapy in recurrent
postsurgical pericardial effusion.
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